Focus On Refurbishing: US FDA Seeks Input On Practices That Extend The Life Of Devices
This article was originally published in SRA
Refurbishing medical devices is a major business, but the practice might require more regulatory attention, the US Food and Drug Administration suggests.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.